Iet uz pamatdaļu

Beta thalassaemia intermedia un Thalassaemia minor

Atbalsta terapija

Dzelzs helātu veidošanās

Iron out for nontransfused thalassemia. (opens new window)

Marks PW.

Avots‎: Blood 2012;120(5):928-9.

Raksts indeksēts‎: PubMed 22859709

DOI‎: 10.1182/blood-2012-06-433227

https://www.ncbi.nlm.nih.gov/pubmed/22859709 (opens new window)

Iron overload in β-thalassemia intermedia: an emerging concern. (opens new window)

Musallam KM, Cappellini MD, Taher AT.

Avots‎: Curr Opin Hematol 2013;20(3):187-92.

Raksts indeksēts‎: PubMed 23426199

DOI‎: 10.1097/MOH.0b013e32835f5a5c

https://www.ncbi.nlm.nih.gov/pubmed/23426199 (opens new window)

Uztura bagātinātāji un cita papildu terapija

Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. (opens new window)

Anthi A, Tsangaris I, Hamodraka ES, Lekakis J, Armaganidis A, Orfanos SE.

Avots‎: Blood 2012;120(7):1531-2.

Raksts indeksēts‎: PubMed 22899478

DOI‎: 10.1182/blood-2012-04-422568

https://www.ncbi.nlm.nih.gov/pubmed/22899478 (opens new window)

Prevalance of iron deficiency in thalassemia minor: a study from tertiary hospital. (opens new window)

Dolai TK, Nataraj KS, Sinha N, Mishra S, Bhattacharya M, Ghosh MK.

Avots‎: Indian J Hematol Blood Transfus 2012;28(1):7-9.

Raksts indeksēts‎: PubMed 23449336

DOI‎: 10.1007/s12288-011-0088-9

https://www.ncbi.nlm.nih.gov/pubmed/23449336 (opens new window)

Therapeutic roles of curcumin: lessons learned from clinical trials. (opens new window)

Gupta SC, Patchva S, Aggarwal BB.

Avots‎: AAPS J 2013;15(1):195-218.

Raksts indeksēts‎: PubMed 23143785

DOI‎: 10.1208/s12248-012-9432-8

https://www.ncbi.nlm.nih.gov/pubmed/23143785 (opens new window)

Vitamin E supplement improves erythrocyte membrane fluidity of thalassemia: an ESR spin labeling study. (opens new window)

Sutipornpalangkul W, Morales NP, Unchern S, Sanvarinda Y, Chantharaksri U, Fucharoen S.

Avots‎: J Med Assoc Thai 2012;95(1):29-36.

Raksts indeksēts‎: PubMed 22379738

https://www.ncbi.nlm.nih.gov/pubmed/22379738 (opens new window)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. (opens new window)

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD.

Avots‎: Am J Hematol 2013;88(6):503-6.

Raksts indeksēts‎: PubMed 23553596

DOI‎: 10.1002/ajh.23445

https://www.ncbi.nlm.nih.gov/pubmed/23553596 (opens new window)